LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Has the World's Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes [TheStreet.com]
Lixte Biotechnology Holdings, Inc. (LIXT)
NASDAQ:AMEX Investor Relations:
lixte.com/investor_information_02.php
Company Research
Source: TheStreet.com
LB-100 helps in the fight against cancer in a few ways, as it makes cancer cells more sensitive to immunotherapy and chemotherapy, while also disrupting cancer's internal repair system. The compound has demonstrated a favorable safety profile in Phase 1 clinical trials and has been supported by over 25 published preclinical and translational studies so far. LIXTE Biotechnology Holdings (NASDAQ: LIXT) , a clinical-stage pharmaceutical company, is in the unique position of holding the world's only clinical-stage protein phosphatase 2A (“PP2A”) inhibitor, called LB-100. The LB-100 compound is a proprietary small-molecule PP2A inhibitor that is designed to target protein phosphatase 2A (“PP2A”), introducing a potential new treatment paradigm aimed at enhancing existing… Read More NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company's newsroom at ibn.fm/LIXT About BioMedWire BioMedWire (“BMW”) is a specialized communications platform w
Show less
Read more
Impact Snapshot
Event Time:
LIXT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LIXT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LIXT alerts
High impacting Lixte Biotechnology Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
LIXT
News
- MissionIRNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Files 2025 Form 10-K, Highlights Transformational Year [TheStreet.com]TheStreet.com
- LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative YearGlobeNewswire
- LIXTE Biotechnology (LIXT) Strengthens Oncology Pipeline Through Expanded LB-100 Clinical Trials [Yahoo! Finance]Yahoo! Finance
- LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. SubsidiaryGlobeNewswire
- DE LA SOUL-LED “GOOD HEALTH SUMMIT” LAUNCHES FEBRUARY 19 AT MOREHOUSE COLLEGE [Yahoo! Finance]Yahoo! Finance
LIXT
Sec Filings
- 3/31/26 - Form 10-K
- 3/20/26 - Form 8-K
- 3/10/26 - Form 8-K
- LIXT's page on the SEC website